Trial Condition(s):

Prostate Cancer

Study to gather information about the use of healthcare services and the way the disease is cared for in Canadian patients with prostate gland cancer which spread throughout the body (REACTIVATE)

Bayer Identifier:

20949

ClinicalTrials.gov Identifier:

NCT04281147

EudraCT Number:

Not Available

Study Completed

Trial Purpose

Study to gather information about the optimal placement of Ra-223 in the order of different treatments in terms of the effect on patients and in terms of the use of healthcare services for the treatment of Canadian patients with prostate gland cancer which spread to other parts of the body. In order to collect this information real world data from prostate gland cancer patients from four Canadian administrative databases will be analyzed.

Data collected from patients treated with their 2nd line of life-prolonging therapy for Non-Metastatic Castration Resistant Prostate Cancer (mCRPC) initiated from 01 Jan 2012 to 31 Dec 2017. For patients included in the study, all available data from the beginning for their record until death, lost to follow-up or database cut-off will be included. The index date is the date of initiation of the 2nd line life-prolonging therapy for mCRPC.

Inclusion Criteria
- Use of at least 2 lines of life-prolonging mCRPC therapy 
- The 2nd line of life-prolonging therapy was initiated between 01-Jan-2012 to 31-Dec-2017
Exclusion Criteria
- No formal exclusion criteria will be applied in order to capture real world use of Ra-223

Trial Summary

Enrollment Goal
4301
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Multiple Locations

Many Locations, Canada

Status
Completed
 

Trial Design